Results 21 to 30 of about 6,775 (167)
The clinical development of obinutuzumab for the treatment of follicular lymphoma [PDF]
Cancer Management and Research, 2017 Barbara Ma,1 Chaitra Ujjani2 1Department of Medicine, 2Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC, USA Abstract: Impressive progress has been made in recent decades for advanced-stage follicular lymphoma ...
Ma B, Ujjani C
doaj +1 more source
Obinutuzumab in Refractory Membranous Nephropathy: A Case Series
Kidney MedicineRationale & Objective: Membranous nephropathy (MN), recognized as an autoimmune kidney disease, responds well to anti-CD20 monoclonal antibodies. Obinutuzumab, a type Ⅱ humanized anti-CD20 and immunoglobulin G1 Fc-optimized monoclonal antibody, when ...
Jianghua Chen, Xin Lei
exaly +3 more sources
BMC Cancer, 2022 Background Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in North America. Previous studies have shown improved progression free survival (PFS) and response rates in unfit patients treated with obinutuzumab compared to other ...
Nicole Bourrier +11 more
doaj +1 more source
Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab [PDF]
Pharmacogenomics and Personalized Medicine, 2014 Lukáš Smolej 4th Department of Internal Medicine – Hematology, University Hospital Hradec Králové and Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech
Smolej L
doaj +1 more source
Obinutuzumab as treatment for ANCA-associated vasculitis [PDF]
, 2021 International audienceAbstract Objectives Rituximab is a standard of care therapy for patients with ANCA-associated vasculitis. When rituximab is contraindicated, or in the case of refractory disease, other treatments are needed.
Langford, Carol +6 more
core +1 more source
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14):follow-up results from a multicentre, open-label, randomised, phase 3 trial [PDF]
, 2020 Background: Venetoclax plus obinutuzumab has been established as a fixed-duration treatment regimen for patients with chronic lymphocytic leukaemia.
Tandon, Maneesh +25 more
core +1 more source
Haematologica, 2018 The safety of obinutuzumab, alone or with chemotherapy, was studied in a non-randomized, open-label, non-comparative, phase IIIb study (GREEN) in previously untreated or relapsed/refractory chronic lymphocytic leukemia.
Véronique Leblond +12 more
doaj +1 more source
Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
Frontiers in Pharmacology, 2023 Introduction: Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, is authorized for the treatment of chronic lymphocytic leukemia (CLL). This study aims to explore the cardiac safety profile of ibrutinib in comparison with obinutuzumab.Methods: A ...
Annamaria Mascolo +15 more
doaj +1 more source
Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12. [PDF]
, 2016 [First paragraph] Obinutuzumab, an afucosylated, type 2 anti-CD20 antibody, showed superior results to rituximab in a head-to-head comparison in combination with chlorambucil in the first-line treatment of chronic lymphocytic leukaemia (CLL) patients ...
M. Lyttelton (7738970) +5 more
core +2 more sources
Hematology/Oncology and Stem Cell Therapy, 2017 Objective/background: Membranoproliferative glomerulonephritis (MPGN) is a common extramedullary renal presentation in chronic lymphocytic leukemia (CLL) and can present with either a frank renal failure or proteinuria.
Punit Jain +5 more
doaj +1 more source